MADRID, April 29, 2010 /PRNewswire/ -- Consolidated revenues for Zeltia (ZEL.MC) amounted to 32.9 million euro in 1Q10, up 49% with respect to 1Q09. Net income improved 50%.
Net revenues in biopharmaceuticals rose 90.9%, primarily due to Yondelis(R) sales, which totalled 16.6 million euro in the first quarter. Almost 60 countries worldwide have authorised the sale of Yondelis(R).
Genómica increased total sales by 29.5% to 1.8 million euro.
Consumer chemical sales amounted to 14.3 million euro, an increase of 16.5% compared with 1Q09, despite the adverse economic situation, which has affected spending.
The company reached EBITDA break-even (68 thousand euro). EBITDA in 1Q09 was -1.1 million euro despite including 7.8 million euro in revenues for licensing Yondelis(R) to Taiho Pharmaceutical Co. in Japan.
The bottom line reflects a 50% improvement in losses (-1.96 million euro in 1Q10, compared with -3.91 million euro in 1Q09).
The Group's net cash position (cash + cash equivalents - short-term bank debt) amounted to 25.2 million euro.
About Zeltia:
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative central nervous system diseases; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.
For information: Tel. +34-91-444-45-00 Capital Markets Department José Luis Moreno Florencia Radizza Media relations Fernando Mugarza
This press release is also available in the Current events section on Zeltia's web site: http://www.zeltia.com
SOURCE: Zeltia
CONTACT: Capital Markets Department: José Luis Moreno or FlorenciaRadizza; or Media relations: Fernando Mugarza, Tel. +34-91-444-45-00
Comments